Home | Site Map | About | Contact 
  The scientific approach to weight loss and maintenance. Indepenent, hype-free research.
 
Weight Loss Guide
 Weight Loss Basics
 Diets & Dieting
 Drug Therapy
 Supplements
 Weight Loss Surgery
 Tools & Calculators
 
News & Research
 Weight Loss News
 Published Studies
   > Drugs
   > Diets
   > Supplements
   > Surgery
   > Lifestyle
 Clinical Trials
 
 
 
 
 
 
 
   
You are here: Published Weight Loss Studies >

Fluoxetine: a randomized clinical trial in the maintenance of weight loss.

Author: Goldstein DJ, Rampey AH Jr, Dornseif BE, Levine LR, Potvin JH, Fludzinski LA

Author affiliation: Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN 46285, USA.

Publication date & source: 1993.03, Obes Res., 1(2):92-8.

Publication type: Multicenter Study; Randomized Controlled Trial

Because current weight-reduction treatments have considerable recidivism, a therapy that could help patients maintain weight loss would be of benefit. A six-center, randomized, double-blind trial compared the effects of the specific serotonin uptake inhibitor, fluoxetine hydrochloride, and placebo on maintenance of weight loss. Obese outpatients who had lost > or = 3.6 kg after 8 weeks of single-blind fluoxetine 60 mg/day in the qualification phase (N=317 [70.4% of patients entered]; mean +/- standard deviation [SD] weight loss, 6.8 +/- 2.8 kg) were randomly assigned to fluoxetine 20 mg/day (N=104), fluoxetine 60 mg/day (N=106), or placebo (N=107) for 40 weeks (maintenance phase). Patients received minimal nutrition/dietary counseling. Qualification phase clinic visits were biweekly; maintenance phase visits were monthly for 4 months, then bimonthly for 6 months. Patients treated with fluoxetine 60 mg/day continued to lose weight for 8 additional weeks (16 weeks total; maximum mean +/- SD weight loss, 7.2 +/- 4.6 kg); those treated with fluoxetine 20 mg/day or placebo began to regain weight. Mean weights remained below baseline values at week 48 (all groups); treatment differences were not statistically significant. Study completion rates were comparable (fluoxetine 20 mg/day, 67.3%; fluoxetine 60 mg/day, 56.6%; placebo, 67.3%; p = 0.175). Among commonly reported adverse events (> 10% incidence), only asthenia was reported statistically significantly (p < 0.050) more frequently with fluoxetine than with placebo. Few patients discontinued for any single adverse event. Fluoxetine 60 mg/day was effective for a longer period than fluoxetine 20 mg/day or placebo in maintaining weight loss. Overall, fluoxetine was safe and well tolerated.



Indexes of Weight Loss Research Abstracts
Weight Loss Drugs
Weight Loss Diets
Supplements
Bariatric Surgery
Lifestyle


Back to Published Weight Loss Studies

     
-- advertisements --


Copyright © 2006 by Weight-Loss-Science.com
All inormation is for education purposes only and should not be considered as a medical advice.